The approval comes just a few months after Johnson & Johnson’s Janssen Biotech unit handed back rights to the drug in resistant hypertension, although the two companies are still partnered on a follow-up use in pulmonary hypertension. As part of the exit, Idorsia could pay J&J around $340 million to re-acquire rights, with the total amount dependent on regulatory and commercial milestones.
